EirGenix Capacity Update May 2024: Large Molecule Development

EirGenix is Taiwan's largest CDMO for mammalian and microbial-derived, clinical, and commercial manufacturing of biologics (mAbs, bi-specifics, ADC, recombinant vaccines, and pDNA). We are inspected and approved by the USFDA, Japan’s PMDA, Australia’s TGA, and the EU’s EMA. EirGenix has immediate capacity availability up to 12 x 2,000 L SUBs for mammalian cells and up to 150 L scale for microbial. The microbial capacity will increase to 350L and 1,000L by 2025.